Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added more...looks like play of day
Nice grab..i had and hold a few..in 1.05 and 1.07
Filled Buy 2225 NAVB Limit 0.96 -- -- 07:52:37 10/29/19
Filled Buy 775 NAVB Limit 0.96 -- -- 07:52:25 10/29/19
Filled Buy 3000 NAVB Limit 1.04 -- -- 07:49:37 10/29/19
Filled Buy 3627 NAVB Limit 1.07 -- -- 07:48:09 10/29/19
News: $NAVB Navidea Biopharmaceuticals Announces Receipt of Notice of Award
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced receipt of the Notice of Award from the National Heart, Lung, and ...
Got this from Navidea Biopharmaceuticals Announces Receipt of Notice of Award
Its still going to go to the single digits again.
This is what always happens to a reverse split.
DOWN DOWN DOWN !!!!!!!!!!!!!
Same ole shit again
Nothing has changed I will shit in my hat if this gets back to were it was at revers split.
This got a $2 target price yesterday. Time for a bounce above .75 to fill the gap at $1. Beat down yesterday was bs.
NAVB~~UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Navidea Biopharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
63937X202
(CUSIP Number)
John K. Scott, Jr.
5251 DTC Parkway, Suite 285
Greenwood Village, CO 80111
Tel: (303) 399-6177
With a Copy to:
James G. Ruiz
Winstead PC
401 Congress Ave
Suite 2100
Austin, Texas 78701
Tel: (512) 370-2800
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
June 14, 2019
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ?
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
CUSIP No. 63937X202
1
NAME OF REPORTING PERSONS
John K. Scott, Jr.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ? (b) ?
3
SEC USE ONLY
4
SOURCE OF FUNDS
PF, OO
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
?
6
CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES OF AMERICA
NUMBER OF
UNITS
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
5,113,078
8
SHARED VOTING POWER
10,139 (1)
9
SOLE DISPOSITIVE POWER
5,113,078
10
SHARED DISPOSITIVE POWER
10,139 (1)
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,123,217 (1)
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
?
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
28.4% (2)
14
TYPE OF REPORTING PERSON
IN
(1)
Includes 2,639 shares of Common Stock owned by the Reporting Person’s spouse and 7,500 shares of Common Stock owned by the Reporting Person’s children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares.
(2)
Based on 18,059,406 shares of Common Stock outstanding as of June 18, 2019, upon the closing of the Issuer’s underwritten public offering, as reported in the Issuer’s prospectus dated June 13, 2019 filed with the Securities and Exchange Commission on June 17, 2019 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.
Item 1.
SECURITY AND ISSUER
The name of the issuer is Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive offices is 4995 Bradenton Avenue, Suite 240, Dublin, Ohio 43017-3552. This Schedule 13D relates to the Issuer’s common stock, par value $0.001 per share (the “Common Stock”).
Item 2.
IDENTITY AND BACKGROUND
(a) This Schedule 13D is being filed by John K. Scott, Jr. (the “Reporting Person”), a natural person.
(b) The Reporting Person’s business address is 5251 DTC Parkway, Suite 285, Greenwood Village, CO 80111.
(c) The Reporting Person’s principal occupation is a self-employed investor. The Reporting Person’s business address is 5251 DTC Parkway, Suite 285, Greenwood Village, CO 80111.
(d) The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f) The Reporting Person is a citizen of the United States.
Item 3.
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Effective April 26, 2019, the Issuer effected a 1-for-20 reverse stock split of its outstanding Common Stock. Where applicable, Common Stock share amounts described below have been adjusted to give effect to the 1-for-20 reverse stock split, with fractional shares rounded down to the nearest whole share.
On September 17, 2018, the Reporting Person purchased 916,030 shares of Common Stock for an aggregate purchase price of $3,000,000 from the Company in a private placement pursuant to a Stock Purchase Agreement, dated September 13, 2018, by and between the Company and the Reporting Person (the “September Purchase Agreement”). Prior to the closing of the transactions contemplated by the September Purchase Agreement, the Reporting Person had acquired 179,190 shares of Common Stock in open market purchases. The aggregate purchase price for such 179,190 shares was approximately $1,300,000.
On March 22, 2019, the Reporting Person purchased 17,857 shares of Common Stock for an aggregate purchase price of $50,000 from the Company in a private placement pursuant to a Stock Purchase Agreement, dated March 22, 2019, by and between the Company and the Reporting Person (the “March Purchase Agreement”). While the March Purchase Agreement contemplated subsequent closings at which the Reporting Person would acquire additional shares of Common Stock, no such subsequent closings occurred, and no additional shares of Common Stock were acquired pursuant to the March Purchase Agreement.
On June 13, 2019, the Issuer entered into an underwriting agreement relating to an underwritten public offering of 8,000,000 shares of Common Stock. The Reporting Person purchased 4,000,000 shares of Common Stock from the underwriter in the underwritten public offering for an aggregate purchase price of $3,000,000. The closing of such purchase occurred on June 18, 2019.
The funds used for the purchase of the 179,190 shares of Common Stock in the open market were derived from personal funds of the Reporting Person. The funds used for the purchase of the remaining shares of Common Stock reported in this Item 3 of this Schedule 13D were derived from a revolving line of credit (the “Revolving Line of Credit”) entered into by and between the Reporting Person and Phelps Tointon, Inc. that has been in effect since June 4, 2010 and from which the Reporting Person draws for the Reporting Person’s general investments. Contact information for Phelps Tointon, Inc. is PO Box 9, Greeley, Colorado, 80632, Attn: Travis Gillmore, Tel: (970) 353-7000.
3
Item 4.
PURPOSE OF TRANSACTION
The Reporting Person acquired the shares of Common Stock reported in this Schedule 13D for investment purposes. As of the date of this Schedule 13D, the Reporting Person has no plans or proposals that relate to, or that would result in, any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D; however, as part of the Reporting Person’s ongoing evaluation of the investment described in this Schedule 13D, the Reporting Person retains the right to change his investment intent and may, from time to time, acquire additional shares of Common Stock or other securities of the Issuer, or sell or otherwise dispose of (or enter into plans or arrangements to sell or otherwise dispose of), all or part of the shares of Common Stock or other securities of the Issuer, if any, beneficially owned by him, in any manner permitted by law.
Item 5.
INTEREST IN SECURITIES OF THE ISSUER
(a) - (b)
The aggregate number and percentage of Common Stock beneficially owned by the Reporting Person are as follows:
Aggregate amount beneficially owned:
5,123,217
(1
)
Percent of class:
28.4
%
(2
)
Number of shares as to which the Reporting Person has:
Sole power to vote or direct the vote:
5,113,078
Shared power to vote or direct the vote:
10,139
(1
)
Sole power to dispose or direct the disposition of:
5,113,078
Shared power to dispose or direct the disposition of:
10,139
(1
)
(1)
Includes 2,639 shares of Common Stock owned by the Reporting Person’s spouse and 7,500 shares of Common Stock owned by the Reporting Person’s children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares.
(2)
Based on 18,059,406 shares of Common Stock outstanding as of June 18, 2019, upon the closing of the Issuer’s underwritten public offering, as reported in the Issuer’s prospectus dated June 13, 2019 filed with the Securities and Exchange Commission on June 17, 2019 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.
(c) On June 13, 2019, the Issuer entered into an underwriting agreement relating to an underwritten public offering of 8,000,000 shares of Common Stock. The Reporting Person purchased 4,000,000 shares of Common Stock at $0.75 per share from the underwriter in the underwritten public offering for an aggregate purchase price of $3,000,000. The closing of such purchase occurred on June 18, 2019. Other than as described in this paragraph, the Reporting Person has not acquired or disposed of any securities of the Issuer from the 60 days prior to the date of the event which requires the filing of this Schedule 13D.
(d) Except as set forth herein, no other person is known by the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Person.
(e) Not applicable.
Item 6.
CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
Pursuant to the terms of the March Purchase Agreement, the Reporting Person agreed to a lock-up agreement with the Issuer, pursuant to which the Reporting Person agreed not to sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of or otherwise dispose of any shares of Common Stock purchased pursuant to the March Purchase Agreement until the expiration of more than 180 days following each closing date under the March Purchase Agreement.
4
As of filing of this Schedule 13D, 4,933,888 of the shares of Common Stock reported on this Schedule 13D as beneficially owned by the Reporting Person were pledged to Phelps Tointon, Inc. in connection with the Revolving Line of Credit.
Except as described in this Item 6, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
Item 7.
MATERIAL TO BE FILED AS EXHIBITS
Exhibit A:
Stock Purchase Agreement, dated March 22, 2019, between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr. (incorporated herein by reference to Exhibit 10.1 to the Issuer’s Quarterly Report on Form 10-Q filed May 9, 2019).
5
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: June 24, 2019
/s/ John K. Scott, Jr.
I like the way you think.
NAVB~HUGE INSIDER BUY,4,000,000 shares at .75SEC Form 4
FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:
3235-0287
Expires:
December 31, 2014
Estimated average burden
hours per response:
0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Scott John K Jr.
(Last)
(First)
(Middle)
5251 DTC PARKWAY, SUITE 285
(Street)
GREENWOOD VILLAGE
CO
80111
(City)
(State)
(Zip)
2. Issuer Name and Ticker or Trading Symbol
NAVIDEA BIOPHARMACEUTICALS, INC. [ NAVB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
X
10% Owner
Officer (give title below)
Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2019
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X
Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
2. Transaction Date (Month/Day/Year)
2A. Deemed Execution Date, if any (Month/Day/Year)
3. Transaction Code (Instr. 8)
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code
V
Amount
(A) or (D)
Price
Common Stock
06/18/2019
P
4,000,000
A
$0.75
5,113,078
D
Common Stock
2,639
I
By Spouse
Common Stock
2,500(1)
I
By Daughter
Common Stock
2,500(1)
I
By Son
Common Stock
2,500(1)
I
By Son
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)
2. Conversion or Exercise Price of Derivative Security
3. Transaction Date (Month/Day/Year)
3A. Deemed Execution Date, if any (Month/Day/Year)
4. Transaction Code (Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date (Month/Day/Year)
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
8. Price of Derivative Security (Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code
V
(A)
(D)
Date Exercisable
Expiration Date
Title
Amount or Number of Shares
Explanation of Responses:
1. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ John K. Scott, Jr.
06/21/2019
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
NAVB looking great to go https://www.stockscores.com/charts/charts/?ticker=navb
NAVB~~chart turning up north people,it's a buy time now
NAVB will be into dollars next week,maybe $2-3 dollars
NAVB watch for crazy buys ahead
NAVB hold 5 time low .67,great support
* * $NAVB Video Chart 07-11-2019 * *
Link to Video - click here to watch the technical chart video
Some insider bought 4,000,000 shares at $.75 on 6/18.
News: $NAVB Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results of the Company’s NAV3-21 clinical st...
Read the whole news https://marketwirenews.com/news-releases/navidea-biopharmaceuticals-announces-snmmi-press-release-and-recognition-of-phase-1-2-study-results-8403980.html
How do you F over a long term holder of a stock. Do a reverse split and then issue more shares, at a lower price. Reverse splits are a death sentence to a stock holder. Never does this work out for you, its more like legal theft. This should not be allowed to happen.
I will chit in my hat if i ever see a return on my money!!
Pissed offed MF
Analysis: Positioning to Benefit within Foamix Pharmaceuticals, Era Group, Orion Group, Intermolecular, Navidea Biopharmaceuticals, and Evelo Biosciences -- Research Highlights Growth, Revenue, and Consolidated Results
8:55 am ET April 17, 2019 (Globe Newswire) Print
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Era Group, Inc. (NYSE:ERA), Orion Group Holdings, Inc. (NYSE:ORN), Intermolecular, Inc. (NASDAQ:IMI), Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), and Evelo Biosciences, Inc. (NASDAQ:EVLO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
FOMX DOWNLOAD: http://Capital-Review.com/register/?so=FOMX
ERA DOWNLOAD: http://Capital-Review.com/register/?so=ERA
ORN DOWNLOAD: http://Capital-Review.com/register/?so=ORN
IMI DOWNLOAD: http://Capital-Review.com/register/?so=IMI
NAVB DOWNLOAD: http://Capital-Review.com/register/?so=NAVB
EVLO DOWNLOAD: http://Capital-Review.com/register/?so=EVLO
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Era Group, Inc. (NYSE:ERA), Orion Group Holdings, Inc. (NYSE:ORN), Intermolecular, Inc. (NASDAQ:IMI), Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), and Evelo Biosciences, Inc. (NASDAQ:EVLO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
FOAMIX PHARMACEUTICALS LTD. (FOMX) REPORT OVERVIEW
Foamix Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Foamix Pharmaceuticals reported revenue of $0.86MM vs $1.04MM (down 17.55%) and analysts estimated basic earnings per share -$0.17 vs -$0.46. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Foamix Pharmaceuticals reported revenue of $3.60MM vs $3.67MM (down 2.02%) and analysts estimated basic earnings per share -$1.70 vs -$1.76. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.69. The estimated EPS forecast for the next fiscal year is -$1.32 and is expected to report on February 27th, 2020.
To read the full Foamix Pharmaceuticals Ltd. (FOMX) report, download it here: http://Capital-Review.com/register/?so=FOMX
-----------------------------------------
ERA GROUP, INC. (ERA) REPORT OVERVIEW
Era Group's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Era Group reported revenue of $52.02MM vs $57.53MM (down 9.59%) and analysts estimated basic earnings per share -$0.25 vs $2.95. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Era Group reported revenue of $221.68MM vs $231.32MM (down 4.17%) and analysts estimated basic earnings per share $0.64 vs -$1.36. Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Era Group, Inc. (ERA) report, download it here: http://Capital-Review.com/register/?so=ERA
-----------------------------------------
ORION GROUP HOLDINGS, INC. (ORN) REPORT OVERVIEW
Orion Group's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Orion Group reported revenue of $99.21MM vs $162.21MM (down 38.84%) and analysts estimated basic earnings per share -$3.32 vs $0.34. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Orion Group reported revenue of $520.89MM vs $578.55MM (down 9.97%) and analysts estimated basic earnings per share -$3.31 vs $0.01. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.01. The estimated EPS forecast for the next fiscal year is $0.14 and is expected to report on March 24th, 2020.
To read the full Orion Group Holdings, Inc. (ORN) report, download it here: http://Capital-Review.com/register/?so=ORN
-----------------------------------------
INTERMOLECULAR, INC. (IMI) REPORT OVERVIEW
Intermolecular's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Intermolecular reported revenue of $6.32MM vs $10.55MM (down 40.07%) and basic earnings per share -$0.06 vs $0.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Intermolecular reported revenue of $33.66MM vs $37.20MM (down 9.52%) and analysts estimated basic earnings per share -$0.07 vs -$0.21. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Intermolecular, Inc. (IMI) report, download it here: http://Capital-Review.com/register/?so=IMI
-----------------------------------------
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) REPORT OVERVIEW
Navidea Biopharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Navidea Biopharmaceuticals reported revenue of $0.12MM vs $0.40MM (down 69.81%) and analysts estimated basic earnings per share -$0.01 vs -$0.02. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Navidea Biopharmaceuticals reported revenue of $1.17MM vs $1.81MM (down 35.41%) and analysts estimated basic earnings per share -$0.09 vs $0.47. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Navidea Biopharmaceuticals, Inc. (NAVB) report, download it here: http://Capital-Review.com/register/?so=NAVB
-----------------------------------------
* * $NAVB Video Chart 04-08-2019 * *
Link to Video - click here to watch the technical chart video
Yeah I read that as well and I also read the compliance targets for companies listed with NYSE
I still need to know what the share price should be..
News: $NAVB Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates
Company Will Host Conference Call at 5:00 p.m. (ET) on Monday, April 8, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutic...
In case you are interested https://marketwirenews.com/news-releases/navidea-biopharmaceuticals-receives-fda-feedback-regarding-rheumatoid-arthritis-clinical-trial-design-and-provides-business-updates-7962016.html
What price does the share need to be according to you?
Too bad talks of R/S is in the works. Though, if the price gets them compliant before the 15th, it may be avoided. maybe we find out this afternoon what the plans will be if they have changed.
Seriously 15 c. Come on.
Still breaking out! Eom
.32c pop for breakout
pullback is here, bottom should be that if going higher. if so .30c is gone
I'm in let's go breaking .29 is big
NAVB something's going on here, buyers on 1min .219
Wow. Showing. 24 c. That would be great
I’m amazed. At this level why some big bio Pharma. Doesn’t buy us out. Hmmmm
I WONDER HOW MANY OF THE OFFICERS BELIEVE THEY DESERVE A BONUS.
From what i have seen most of them need to back up for there regular pay to receive it as big as it is. As for most of us who have invested in this company only watched our money go into thin air. With nothing to show but losses.Now they want to do a reverse split less shares and then watch them tank. Most of the time RS are lazy & bad management that caused the RS anyway. PISSSED!!!!!
Conference Call
Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial
Download as PDF April 03, 2018
Conference call to take place Thursday April 5, 2018 at 8:30am E.T.
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on April 5, 2018 at 8:30am E.T. to discuss its future outlook following the outcome of the court case in Texas with Capital Royalty Group (CRG).
Michael Goldberg, President and Chief Executive Officer, and Jed Latkin, Chief Financial and Operating Officer of Navidea, will host the call and provide an update on recent developments and the strategy going forward.
To participate in the call, please dial +1 929-477-0448 (toll-free) in the U.S. and Canada. The conference ID number is 6756561.
Event: Navidea Future Outlook and Trial Outcome Call
Date: Thursday, April 5, 2018
Time: 8:30am E.T.
U.S. & Canada Dial-in: +1 929-477-0448 (toll free)
Conference ID: 6756561
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
I sure hope he meets a NAVB investor or two in the shower !!!
For once, justice prevails! While former investors of NAVB will likely never be compensated for the destruction Shkreli had upon various stocks through manipulation, I'm at least satisfied that he didn't get away scott free with all of his illegal activities.
https://www.cnbc.com/2018/03/09/pharma-bro-martin-shkreli-sentenced-to-7-years-in-prison.html
I see there's still nothing going on here with NAVB.
Lost a LOT of $$$ back when Shkreli & Co came out and trashed the company nonstop with their social media networks and websites a few years back. Clearly the man was right to a degree about Lymphoseek not being worth much, but still what he and his cohorts did was sickening and illegal, and I'd love to see the book thrown at him.
Investors could have lost enough on their own with a dud like Lymphoseek and didn't need the help of Shkreli to trash the stock. What he did with filing a citizen's petition to try and halt or delay the drug was just criminal, since he was a known shorter and had a financial interest in the destruction of the stock. In a way, what he did was nothing short of a pyramid scheme, and being either being born and raised in Albania during the 1990s, or having connections there, he likely new full well of how to scheme others into losing $$$$. I had relatives living there as missionaries for many years, and a lot of their friends unfortunately lost their entire savings to pyramid schemes.
Spotlight partner. http://nash-summit.com/partner/partners
Navidea to Host Moderated Q&A Webcast with Management
Download as PDF
February 01, 2018
Webcast is scheduled with CFO Jed Latkin for Tuesday, February 13th at 5:00 p.m. ET
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session with Jed Latkin, Chief Financial and Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer of Navidea, on Tuesday February 13, 2018 at 5:00 p.m. Eastern Time. Investors are invited to submit questions they would like to hear answered to ir@navidea.com or tpatel@edisongroup.com by Friday, February 9, 2018.
From time to time, between quarterly conference calls, the management will host Q&A webcasts so investors and potential investors can learn more about the Company, its strategy, and its products.
Event:
Navidea Q&A Session – February 2018
Date:
Tuesday, February 13th, 2018
Time:
5:00 p.m. Eastern
US/Canada Toll-Free:
800-239-9838
Conference ID:
9621939
Webcast:
http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=5287
Nice day today with trading/volume. IMO
Getting interest. Navidea will have a positive 2018. IMO
Thanks and good luck!
Followers
|
209
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9289
|
Created
|
11/25/01
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |